Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C16H20N2 |
| Molecular Weight | 240.3434 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CN(C)CCC(C1=CC=CC=C1)C2=CC=CC=N2
InChI
InChIKey=IJHNSHDBIRRJRN-UHFFFAOYSA-N
InChI=1S/C16H20N2/c1-18(2)13-11-15(14-8-4-3-5-9-14)16-10-6-7-12-17-16/h3-10,12,15H,11,13H2,1-2H3
| Molecular Formula | C16H20N2 |
| Molecular Weight | 240.3434 |
| Charge | 0 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
DescriptionSources: https://www.drugs.com/drp/pheniramine-maleate.html | http://www.news-medical.net/drugs/Avil.aspxCurator's Comment: Description was created based on several sources, including http://www.druginfosys.com/drug.aspx?drugcode=561&type=1 | https://www.drugbank.ca/drugs/DB01620
Sources: https://www.drugs.com/drp/pheniramine-maleate.html | http://www.news-medical.net/drugs/Avil.aspx
Curator's Comment: Description was created based on several sources, including http://www.druginfosys.com/drug.aspx?drugcode=561&type=1 | https://www.drugbank.ca/drugs/DB01620
Pheniramine is an antihistamine used to treat allergic conditions such as hay fever or urticaria. It is generally sold in combination with other medications, rather than as a stand-alone drug. Allergies are caused by an excessive type 1 hypersensitivity response of the body to allergens, mediated by inappropriate histamine signalling. By inhibiting the binding of histamine, antihistamines decrease the normal histamine response from cells, consequently decreasing allergic symptoms. Antihistamines such as pheniramine appear to compete with histamine for histamine H1- receptor sites on effector cells. The antihistamines antagonize those pharmacological effects of histamine which are mediated through activation of H1- receptor sites and thereby reduce the intensity of allergic reactions and tissue injury response involving histamine release. Antihistamines suppress the histamine-induced wheal (swelling) and flare (vasodilation) response by blocking the binding of histamine to its receptors on nerves, vascular smooth muscle, glandular cells, endothelium, and mast cells. They effectively exert competitive antagonism of histamine for H1-receptors. Pheniramine is marketed under the trade name Avil and Visine-A among others).
CNS Activity
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL231 |
7.5 null [pKi] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | AVIL Approved UseAllergic conditions including hay fever, drug rashes, angioneurotic oedema, serum sickness,
allergic conjunctivitis, food allergy etc.
· Conditions of the respiratory tract that are accompanied by increased secretion, including
vasomotor rhinitis and acute rhinitis.
· All itching skin conditions, including neurodermatitis, eczema of any origin, lichen planus,
acute and chronic urticaria, pruritis of the anus or genitals, pruritus in icterus and diabetes,
radiation sickness etc.
· Prevention and treatment of motion sickness.
· Prevention and treatment of nausea, vomiting and vertigo due to Menière’s disease and other
labyrinthine disturbances. |
|||
| Palliative | Visine-A Approved UseVisine-A is an antihistamine/redness reliever eye drop, formerly available by prescription only, that provides temporary relief of itchy, red eyes due to pollen, ragweed, grass, animal hair and dander. |
|||
| Primary | AVIL Approved UseAllergic conditions including hay fever, drug rashes, angioneurotic oedema, serum sickness,
allergic conjunctivitis, food allergy etc.
· Conditions of the respiratory tract that are accompanied by increased secretion, including
vasomotor rhinitis and acute rhinitis.
· All itching skin conditions, including neurodermatitis, eczema of any origin, lichen planus,
acute and chronic urticaria, pruritis of the anus or genitals, pruritus in icterus and diabetes,
radiation sickness etc.
· Prevention and treatment of motion sickness.
· Prevention and treatment of nausea, vomiting and vertigo due to Menière’s disease and other
labyrinthine disturbances. |
|||
| Preventing | AVIL Approved UseAllergic conditions including hay fever, drug rashes, angioneurotic oedema, serum sickness,
allergic conjunctivitis, food allergy etc.
· Conditions of the respiratory tract that are accompanied by increased secretion, including
vasomotor rhinitis and acute rhinitis.
· All itching skin conditions, including neurodermatitis, eczema of any origin, lichen planus,
acute and chronic urticaria, pruritis of the anus or genitals, pruritus in icterus and diabetes,
radiation sickness etc.
· Prevention and treatment of motion sickness.
· Prevention and treatment of nausea, vomiting and vertigo due to Menière’s disease and other
labyrinthine disturbances. |
|||
| Primary | AVIL Approved UseAllergic conditions including hay fever, drug rashes, angioneurotic oedema, serum sickness,
allergic conjunctivitis, food allergy etc.
· Conditions of the respiratory tract that are accompanied by increased secretion, including
vasomotor rhinitis and acute rhinitis.
· All itching skin conditions, including neurodermatitis, eczema of any origin, lichen planus,
acute and chronic urticaria, pruritis of the anus or genitals, pruritus in icterus and diabetes,
radiation sickness etc.
· Prevention and treatment of motion sickness.
· Prevention and treatment of nausea, vomiting and vertigo due to Menière’s disease and other
labyrinthine disturbances. |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
274 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3988394/ |
30.5 mg single, oral dose: 30.5 mg route of administration: Oral experiment type: SINGLE co-administered: |
PHENIRAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
5768 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3988394/ |
30.5 mg single, oral dose: 30.5 mg route of administration: Oral experiment type: SINGLE co-administered: |
PHENIRAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
17 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3988394/ |
30.5 mg single, oral dose: 30.5 mg route of administration: Oral experiment type: SINGLE co-administered: |
PHENIRAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Rational quantitative structure-activity relationship (RQSAR) screen for PXR and CAR isoform-specific nuclear receptor ligands. | 2010-12-05 |
|
| Use of potentially inappropriate medicines in elderly: A prospective study in medicine out-patient department of a tertiary care teaching hospital. | 2010-04 |
|
| Severe pulmonary adverse effects in lymphoma patients treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen plus rituximab. | 2010-03 |
|
| Substance use and addiction research in India. | 2010-01 |
|
| Indian research on acute organic brain syndrome: Delirium. | 2010-01 |
|
| In vitro antibacterial activity of some systemic and topical antihistaminic preparations. | 2009-12-01 |
|
| Pouch colon associated with anorectal malformations fails to show spontaneous contractions but responds to acetylcholine and histamine in vitro. | 2009-11 |
|
| Halogenation effects of pheniramines on the complexation with beta-cyclodextrin. | 2009-10-15 |
|
| Acute renal failure caused by pheniramine maleate induced rhabdomyolysis: an unusual case. | 2009-10 |
|
| Weekly paclitaxel and trastuzumab as a first-line therapy in patients with HER2-overexpressing metastatic breast cancer: magnitude of HER2/neu amplification as a predictive factor for efficacy. | 2009-10 |
|
| Antihistamine pretreatment to reduce incidence of withdrawal movement after rocuronium injection. | 2009-10 |
|
| Comparison of chiral separation of basic drugs in capillary electrophoresis and liquid chromatography using neutral and negatively charged cyclodextrins. | 2009-07-10 |
|
| Simultaneous determination of pseudoephdrine, pheniramine, guaifenisin, pyrilamine, chlorpheniramine and dextromethorphan in cough and cold medicines by high performance liquid chromatography. | 2009-05-15 |
|
| In situ forming polymeric drug delivery systems. | 2009-05 |
|
| Modulation of in vivo immunoglobulin production by endogenous histamine and H1R and H2R agonists and antagonists. | 2009-04-11 |
|
| Pheniramines and oxidative burst of blood phagocytes during ischaemia/reperfusion. | 2009-04 |
|
| Protective effect of pheniramines against mesenteric ischaemia/reperfusion-induced injury. | 2009-04 |
|
| Preparation and evaluation of orodispersible tablets of pheniramine maleate by effervescent method. | 2009-03 |
|
| A presentation of longstanding toxoplasmosis chorioretinitis. | 2009-01 |
|
| H1-antihistamines and oxidative burst of professional phagocytes. | 2009 |
|
| The effects of dithiaden on nitric oxide production by RAW 264.7 cells. | 2008-12 |
|
| The lollipop with strawberry aroma may be promising in reduction of infusion-related nausea and vomiting during the infusion of cryopreserved peripheral blood stem cells. | 2008-12 |
|
| Techniques of skin biopsy and practical considerations. | 2008-07 |
|
| Uniformly sized molecularly imprinted polymers for d-chlorpheniramine: influence of a porogen on their morphology and enantioselectivity. | 2008-04-14 |
|
| Evaluation of a new premedication protocol for administration of equine rabies immunoglobulin in patients with hypersensitivity. | 2008-02-05 |
|
| Possibilities of column coupling electrophoresis provided with a fiber-based diode array detection in enantioselective analysis of drugs in pharmaceutical and clinical samples. | 2008-01-25 |
|
| [Toxic epidermal necrolysis following dorzolamide eyedrops]. | 2008-01 |
|
| Chiral separation of alkylamine antihistamines in pharmaceuticals by capillary isotachophoresis with charged cyclodextrin. | 2007-11 |
|
| Chemical profile of counterfeit buprenorphine vials seized in Tehran, Iran. | 2007-10-25 |
|
| Enantioselective analysis of pheniramine in urine by charged CD-mediated CZE provided with a fiber-based DAD and an on-line sample pretreatment by capillary ITP. | 2007-08 |
|
| First-generation H1 antihistamines found in pilot fatalities of civil aviation accidents, 1990-2005. | 2007-05 |
|
| High risk behaviors of injection drug users registered with harm reduction programme in Karachi, Pakistan. | 2007-02-10 |
|
| Intraoperative anaphylaxis with a complicated pulmonary hydatid cyst. | 2007-02 |
|
| Extra- and intracellular formation of reactive oxygen species by human neutrophils in the presence of pheniramine, chlorpheniramine and brompheniramine. | 2006-12 |
|
| Goat ureter - an alternative model for measuring ureteral peristalsis. | 2006-08 |
|
| Life-threatening facial edema due to pine caterpillar mimicking an allergic event. | 2006-07-21 |
|
| Antiradical effects of antihistamines in human blood. Structure-activity relationship. | 2006-04 |
|
| Pre-treatment of anaphylaxis, does it really work? | 2005-12 |
|
| Enantioselective determination of pheniramine in pharmaceuticals by capillary electrophoresis with charged cyclodextrin. | 2005-07-01 |
|
| A comparison of the clinical efficacy of pheniramine maleate/naphazoline hydrochloride ophthalmic solution and olopatadine hydrochloride ophthalmic solution in the conjunctival allergen challenge model. | 2005-05 |
|
| A case of pheniramine dependence. | 2005-03 |
|
| [Use of capillary isotachophoresis for the determination of pheniramine in granulated powders]. | 2005-03 |
|
| Rapid identification and quantification of chlorpheniramine maleate or pheniramine maleate in pharmaceutical preparations by thin-layer chromatography-densitometry. | 2005-01-29 |
|
| Actual therapeutic management of allergic and hyperreactive nasal disorders. | 2004 |
|
| Conjunctival allergen challenge: models in the investigation of ocular allergy. | 2003-07 |
|
| Efficacy and safety of rectal thiopental, intramuscular cocktail and rectal midazolam for sedation in children undergoing neuroimaging. | 2002-12 |
|
| Contribution of the histaminergic receptor subtypes to histamine-induced cerebellar granular neurotoxicity. | 2002-04-23 |
|
| A phase II study of paclitaxel and cisplatin combination chemotherapy in recurrent or metastatic head and neck cancer. | 2002-04 |
|
| Uniformly sized molecularly imprinted polymer for d-chlorpheniramine. Evaluation of retention and molecular recognition properties in an aqueous mobile phase. | 2002-03-01 |
|
| [Antimycobacterial antihistaminics]. | 1989-08 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: http://www.medicines.org.au/files/swpavilt.pdf
Curator's Comment: Could also be used topically https://www.drugs.com/drp/pheniramine-maleate.html
Each Avil (Pheniramine maleate) tablet contains 45.3mg pheniramine maleate. In adults and children over 10 years of age, treatment is commenced with half a tablet
taken up to three times daily. This dose may be increased to one tablet taken up to three times daily
if required. Children 5-10 years of age: half a tablet up to three times daily. Avil tablets are not
recommended in children under 5 years of age.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26862290
Histamine (100 uM)-induced contractions was blocked by pheniramine (0.32 uM) by 74% in neonatal small intestinal smooth muscle of dilated pre-atretic part of intestinal atresia.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Apr 02 07:52:53 GMT 2025
by
admin
on
Wed Apr 02 07:52:53 GMT 2025
|
| Record UNII |
134FM9ZZ6M
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
LIVERTOX |
769
Created by
admin on Wed Apr 02 07:52:53 GMT 2025 , Edited by admin on Wed Apr 02 07:52:53 GMT 2025
|
||
|
WHO-ATC |
R06AB05
Created by
admin on Wed Apr 02 07:52:53 GMT 2025 , Edited by admin on Wed Apr 02 07:52:53 GMT 2025
|
||
|
WHO-ATC |
D04AA16
Created by
admin on Wed Apr 02 07:52:53 GMT 2025 , Edited by admin on Wed Apr 02 07:52:53 GMT 2025
|
||
|
WHO-VATC |
QR06AB05
Created by
admin on Wed Apr 02 07:52:53 GMT 2025 , Edited by admin on Wed Apr 02 07:52:53 GMT 2025
|
||
|
NCI_THESAURUS |
C29578
Created by
admin on Wed Apr 02 07:52:53 GMT 2025 , Edited by admin on Wed Apr 02 07:52:53 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID0023454
Created by
admin on Wed Apr 02 07:52:53 GMT 2025 , Edited by admin on Wed Apr 02 07:52:53 GMT 2025
|
PRIMARY | |||
|
155683-10-6
Created by
admin on Wed Apr 02 07:52:53 GMT 2025 , Edited by admin on Wed Apr 02 07:52:53 GMT 2025
|
SUPERSEDED | |||
|
CHEMBL1193
Created by
admin on Wed Apr 02 07:52:53 GMT 2025 , Edited by admin on Wed Apr 02 07:52:53 GMT 2025
|
PRIMARY | |||
|
SUB09768MIG
Created by
admin on Wed Apr 02 07:52:53 GMT 2025 , Edited by admin on Wed Apr 02 07:52:53 GMT 2025
|
PRIMARY | |||
|
201-656-2
Created by
admin on Wed Apr 02 07:52:53 GMT 2025 , Edited by admin on Wed Apr 02 07:52:53 GMT 2025
|
PRIMARY | |||
|
134FM9ZZ6M
Created by
admin on Wed Apr 02 07:52:53 GMT 2025 , Edited by admin on Wed Apr 02 07:52:53 GMT 2025
|
PRIMARY | |||
|
86-21-5
Created by
admin on Wed Apr 02 07:52:53 GMT 2025 , Edited by admin on Wed Apr 02 07:52:53 GMT 2025
|
PRIMARY | |||
|
DB01620
Created by
admin on Wed Apr 02 07:52:53 GMT 2025 , Edited by admin on Wed Apr 02 07:52:53 GMT 2025
|
PRIMARY | |||
|
134FM9ZZ6M
Created by
admin on Wed Apr 02 07:52:53 GMT 2025 , Edited by admin on Wed Apr 02 07:52:53 GMT 2025
|
PRIMARY | |||
|
100000082237
Created by
admin on Wed Apr 02 07:52:53 GMT 2025 , Edited by admin on Wed Apr 02 07:52:53 GMT 2025
|
PRIMARY | |||
|
8132
Created by
admin on Wed Apr 02 07:52:53 GMT 2025 , Edited by admin on Wed Apr 02 07:52:53 GMT 2025
|
PRIMARY | RxNorm | ||
|
m8619
Created by
admin on Wed Apr 02 07:52:53 GMT 2025 , Edited by admin on Wed Apr 02 07:52:53 GMT 2025
|
PRIMARY | Merck Index | ||
|
47965
Created by
admin on Wed Apr 02 07:52:53 GMT 2025 , Edited by admin on Wed Apr 02 07:52:53 GMT 2025
|
PRIMARY | |||
|
2132
Created by
admin on Wed Apr 02 07:52:53 GMT 2025 , Edited by admin on Wed Apr 02 07:52:53 GMT 2025
|
PRIMARY | |||
|
D010632
Created by
admin on Wed Apr 02 07:52:53 GMT 2025 , Edited by admin on Wed Apr 02 07:52:53 GMT 2025
|
PRIMARY | |||
|
105
Created by
admin on Wed Apr 02 07:52:53 GMT 2025 , Edited by admin on Wed Apr 02 07:52:53 GMT 2025
|
PRIMARY | |||
|
PHENIRAMINE
Created by
admin on Wed Apr 02 07:52:53 GMT 2025 , Edited by admin on Wed Apr 02 07:52:53 GMT 2025
|
PRIMARY | |||
|
4761
Created by
admin on Wed Apr 02 07:52:53 GMT 2025 , Edited by admin on Wed Apr 02 07:52:53 GMT 2025
|
PRIMARY | |||
|
7267
Created by
admin on Wed Apr 02 07:52:53 GMT 2025 , Edited by admin on Wed Apr 02 07:52:53 GMT 2025
|
PRIMARY | |||
|
C61889
Created by
admin on Wed Apr 02 07:52:53 GMT 2025 , Edited by admin on Wed Apr 02 07:52:53 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
SALT/SOLVATE -> PARENT | |||
|
TARGET -> INHIBITOR | |||
|
|
SALT/SOLVATE -> PARENT | |||
|
|
SALT/SOLVATE -> PARENT | |||
|
|
SALT/SOLVATE -> PARENT |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |